Home

overview

In this interactive webinar Dr Bertrand Tombal and Dr Jonathan Tward explore the evolving treatment landscape in metastatic castration-resistant prostate cancer (mCRPC), from monotherapy to combination approaches, including radioligand therapies. Through 2 patient case studies, they offer keen insights into assessment, treatment selection and sequencing, as well as best practices for multidisciplinary care coordination and collaboration, informed by the latest supporting clinical evidence.

faculty

Panelist

Bertrand Tombal, MD, PhD

Chairman

Department of Surgery

Professor of Urology

Université Catholique de Louvain

Cliniques Universitaires Saint-Luc

Brussels, Belgium

Panelist

Jonathan Tward, MD, PhD, FASTRO

Leader, HCI Genitourinary Cancers Center

The Vincent P. and Janet Mancini Presidential Endowed Chair

in Genitourinary Malignancies

Huntsman Cancer Institute at the University of Utah

Salt Lake City, Utah, United States

AGENDA

1:00 PM TZ

Welcome and Introduction

John Doe, MD

1:30 PM TZ

Introduction Medical Term

Lynn Doe, MD

2:00 PM TZ

Management of Acute Leukemia for the Community Healthcare Team

Jane Doe, MD

2:30 PM TZ

Panel Discussion

Kelly Doe, MD

5:00 PM TZ

Audience Q&A

TARGET AUDIENCE

This educational activity is intended for an audience of hematologists/oncologists, radiologists and urologists.

GOAL STATEMENT

The goal of this activity is for learners to be better able to integrate the latest clinical developments into practice and provide appropriate care to patients with metastatic castration-resistant prostate cancer (mCRPC).

LEARNING OBJECTIVES

Upon completion of this activity, participants will: [break] Have increased knowledge regarding the [LIST] [ITEM]Latest clinical trial data of novel treatment strategies for early mCRPC[/LIST] [break] Have greater competence related to [LIST] [ITEM]Selecting the most optimal treatment regimen for those patients with mCRPC in the early setting [ITEM]Managing patients with mCRPC while on treatment[/LIST] [break] Demonstrate greater confidence in their ability to [LIST] [ITEM]Work efficiently in the multidisciplinary team to identify patients with mCRPC who may benefit from novel and emerging therapies [/LIST]

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

[bold]For Physicians [/bold][break] Medscape, LLC designates this live activity for a maximum of 0.5 [italic]AMA PRA Category 1 Credits™[italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.[break] [bold]For Nurses[/bold][break] Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs.[break] [bold]For Pharmacists[/bold][break] Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-25-059-L01-P).

CME/CNE/CPE